Patents by Inventor Marian Gorecki

Marian Gorecki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5126252
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; an origin of replication and a gene associated with a selectable or identificable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.
    Type: Grant
    Filed: March 1, 1989
    Date of Patent: June 30, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Galadi, Marian Gorecki
  • Patent number: 5112744
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; and ATG initiation codon or DNA which is converted into and ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; and origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.
    Type: Grant
    Filed: June 15, 1990
    Date of Patent: May 12, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Galadi, Marian Gorecki
  • Patent number: 4997916
    Abstract: A method is provided for recovering a purified animal growth hormone or a polypeptide analog thereof having substantially the same amino acid sequence as, and the biological activity of, the corresponding naturally-occurring animal growth hormone from a bacterial cell in which the animal growth hormone or polypeptide analog has been produced by means of expression of a plasmid encoding the hormone or polypeptide analog which comprises: (a) disrupting the cell wall of the bacterial cell in a buffered neutral pH solution so as to produce a lysate containing precipitated hormone or polypeptide analog; (b) recovering the resulting precipitated hormone or polypeptide analog; (c) suspending the precipitated hormone or polypeptide analog so recovered in distilled water; (d) treating the resulting precipitate-containing suspension with a sodium hydroxide solution having an alkaline pH of about 11.
    Type: Grant
    Filed: March 7, 1989
    Date of Patent: March 5, 1991
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 4871835
    Abstract: Analogs of hGH having the activity of naturally occurring hGH and a similar amino acid sequence varying from the sequence of natural hGh by the addition of one or more amino acids, e.g. methione or methionine-leucine, to the N-terminus of natural hGH have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to increase the level of hGH in the subject.Analogs of hGH which comprise the amino acid sequence of natural hGH from the N-terminus of which one or more amino acids have been deleted, e.g. Met.sup.14 hGh, have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to lower the level of hGH in the subject.A plasmid has been constructed which directs the expression of an analog of hGH having the amino acid sequence methionine-leucine added to the N-terminus of natural hGH.
    Type: Grant
    Filed: January 14, 1985
    Date of Patent: October 3, 1989
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Pinhas E. Zeelon, Menachem Zeevi
  • Patent number: 4831120
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: July 3, 1985
    Date of Patent: May 16, 1989
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 4390526
    Abstract: The present invention relates to novel compounds selected from R.sub.1 --COO(CH.sub.2).sub.n --R.sub.2 and ##STR1## wherein R.sub.1 is selected from heterocyclic aromatic and hydrophobic naturally occuring and modified amino acids in the D- and in the L-form, and from peptides, wherein n is an integer of from 1 to 5 and R.sub.2 is selected from unsubstituted and substituted phenyl rings, and from heterocyclic rings, as well as to pharmaceutical compositions for preventing sickling of erythrocytes during sickle cell crisis and for desickling of sickle cells of patients afflicted by sickle cell disease, the active ingredient of which is a compound as defined above.
    Type: Grant
    Filed: June 6, 1980
    Date of Patent: June 28, 1983
    Assignee: Yeda Research & Development Co. Ltd.
    Inventors: Marian Gorecki, Clemenceau T. A. Acquaye, Meir Wilchek, Alexander Rich